Article Details
Retrieved on: 2024-05-23 16:24:10
Tags for this article:
Click the tags to see associated articles and topics
Summary
Merck KGaA's acquisition of Mirus Bio enhances its capabilities in viral vector-based gene therapy production. This integration with MilliporeSigma strengthens its biopharma CDMO services, addressing high demand in gene therapy manufacturing. Tags like Merck Group, Mirus Bio, and Contract manufacturing organization are relevant.
Article found on: www.biopharmadive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here